Skip to main content
SpringerLink
Log in

Psychische Erkrankungen und Diabetes mellitus

Mental disorders and diabetes mellitus

  • leitlinien für die praxis
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Diabetes mellitus ist häufig mit psychischen Erkrankungen assoziiert. Depressive Störungen kommen bei diabetischen PatientInnen doppelt so häufig vor wie in der nicht-diabetischen Population. Andere psychische Erkrankungen, die gehäuft mit Prädiabetes und Diabetes mellitus vorkommen, sind kognitive Dysfunktionen bis zur Demenz, auffälliges Essverhalten, Angststörungen, Schizophrenie, bipolare Störungen und Borderline -Persönlichkeitsstörungen. Die ungünstigen Auswirkungen dieser Koinzidenz auf den Stoffwechsel sind nachhaltig und manifestieren als schlechtere metabolische Kontrolle und vermehrte mikro- und makroangiopathische Komplikationen. Ziel dieses Positionspapieres ist sowohl die Sensibilisierung aller involvierten medizinischen FachkollegInnen sowie sonstiger mit dem Thema befasster Berufsgruppen und Organisationen als auch die Intensivierung der komplexen therapeutischen Interventionen bei PatientInnen. Positive Auswirkungen wären die Verringerung der Inzidenz von Diabetes mellitus bei PatientInnen mit psychischen Erkrankungen, die konsekutive Reduktion von Spätfolgen, insbesondere der kardiovaskulären Morbidität und Mortalität sowie eine verbesserte Lebensqualität der Betroffenen.

Summary

Psychiatric disorders and psychological problems are common in patients with diabetes mellitus. There is a twofold increase in depression which is associated with suboptimal glycemic control and increased morbidity and mortality. Other psychiatric disorders with a higher incidence of diabetes mellitus are cognitive impairment, dementia, disturbed eating behaviour, anxiety disorders, schizophrenia, bipolar disorders and borderline personality disorder. The coincidence of mental disorders and diabetes mellitus has unfavourable influences on metabolic control and micro- and macroangiopathic late complications. Improvement of therapeutic outcome is a challenge in the modern health care system. The intentions behind this position paper are to rise awareness of this special set of problems, to intensify cooperation between involved health care providers and to reduce incidence of diabetes mellitus as well as morbidity and mortality from diabetes in this patient group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24.

    Article  PubMed  Google Scholar 

  2. Fisher L, Plonsky WH, Hessler D, Mullan J. When is diabetes distress clinically meaningful? Diabetes Care. 2012;35:259–64.

    Article  PubMed  PubMed Central  Google Scholar 

  3. American Diabetes Association. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care and immunization. Sec. 4. in Standards of Medical Care in Diabetes – 2015. Diabetes Care. 2015;38 (Suppl 1):S20–30.

    Article  Google Scholar 

  4. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58.

    Article  PubMed  Google Scholar 

  5. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and metaanalysis. Br J Psychiatry. 2008;192(6):406–11.

    Article  CAS  PubMed  Google Scholar 

  6. Katon W, Ming-Yu F, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. J Gen Intern Med. 2008;23(10):1571–5.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sullivan MD, O’Connor P, Feeney P, et al. Depression predicts all-cause mortality. Epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care. 2012;35:1708–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes. Diabetes Care. 2001;24:1069–78.

    Article  CAS  PubMed  Google Scholar 

  9. Abrahamian H, Hofmann P, Prager R, Toplak H. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009;5:261–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49:837–45.

    Article  CAS  PubMed  Google Scholar 

  11. Ali S, Stone A, Peters L, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165–73.

    Article  CAS  PubMed  Google Scholar 

  12. Nicolucci A, Kovacs Burns K, Holt RI, et al. Diabetes attitudes, wishes and Needs second study (DAWN2): crossnational benchmarking of diabetes- related psychosocial outcomes for people with diabetes. Diabet med. 2013;30(7):767–77.

    Article  CAS  PubMed  Google Scholar 

  13. Gonzalez JS, Delahanty LM, Safren SA, Meigs JB, Grant RW. Differentiating symptoms of depression from diabetes-specific distress: relationships with self-care in type 2 diabetes. Diabetologia. 2008;51(10):1822–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Whooley MA, Avins AL, Miranda J, et al. Case-finding instrument for depression. J Gen Intern Med. 1997;12:439–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hautzinger M, Keller F, Kühner C. Beck Depressions-Inventar (BDI-II). Revision. Frankfurt a. M.: Harcourt Test Services; 2006.

    Google Scholar 

  16. Herrmann-Lingen C, Buss U, Snaith RPHADS-D. Hospital Anxiety and Depression Scale – Deutsche Version. 3. aktualisierte Aufl. Bern: Huber; 2011.

    Google Scholar 

  17. Leitlinie der deutschen Diabetesgesellschaft. http://www.deutsche-diabetes-gesellschaft.de. Zugegriffen: 12. Aug. 2015.

  18. Correll CU, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36.

    Google Scholar 

  19. Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009;26(2):153–61.

    Article  CAS  PubMed  Google Scholar 

  20. Ludman E, Katon W, Russo J, et al. Panic episodes among patients with diabetes. Gen Hosp Psychiatry. 2006;28:475–81.

    Article  PubMed  Google Scholar 

  21. Young-Hyman DL, Davis CL. Disordered eating behavior in individuals with diabetes. Diabetes Care. 2010;33:683–9.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Markowitz JT, Butler DA, Vokening LK, et al. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. Diabetes Care. 2010;33:495–500.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kahl KG, Greggersen W, Schweiger U, et al. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci. 2013;263(3):205–13.

    Article  PubMed  Google Scholar 

  24. Mai Qu, CDÀrcy H, Sanfilippo FM, Emery JD, Preen DB. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med. 2011;9:118.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53.

    Article  PubMed  Google Scholar 

  26. Jones BJ, Gallagher BJ, Moss DM, McFalls JA. Obstetrical complications, social class and type of schizophrenia. Clin Schizophr Relat Psychoses. 2011;5(1):33–9.

    Article  PubMed  Google Scholar 

  27. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11.

    Article  CAS  PubMed  Google Scholar 

  28. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes – systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9.

    Article  CAS  PubMed  Google Scholar 

  29. Seaquist E. The final frontier: how does diabetes affect the brain? Diabetes. 2010;59:4–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356(18):1842–52.

    Article  PubMed  Google Scholar 

  31. Hershey T, Perantie DC, Wu J, Weaver PM, Black KJ, White NH. Hippocampal volumes in youth with type 1 diabetes. Diabetes. 2010;59(1):236–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Launer LJ, Miller ME, Williamson JD, et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study. Lancet Neurol. 2011;10(11):969–77.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ress C, Tschoner A, Kaser S, Ebenbichler C. Psychopharmaka und diabetes. Wien Med Wochenschr. 2011;161(21–22):531–42.

    Article  PubMed  Google Scholar 

  34. Bushe CJ, Leonard BE. Blood glucose and schizophrenia – a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007;68(11):1682–90.

    Article  CAS  PubMed  Google Scholar 

  35. Prisciandaro JJ, Gebregziabher M, Grubaugh AL, Gilbert GE, Echols C, Egede LE. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes. Diabetes Technol Ther. 2011;13(1):73–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry. 2004;184:58–62.

    Article  PubMed  Google Scholar 

  37. Funnell MM, Anderson RM. The problem with compliance in diabetes. JAMA. 2000;284(13):1709.

    Article  CAS  PubMed  Google Scholar 

  38. Delamater AM, Jacobson AM, Anderson B, Cox D, Fisher L, et al. Improving patient adherence. Clin Diabetes. 2006;24(2):71–7.

    Article  Google Scholar 

  39. Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes. Diabetes Care. 2001;24:561–8.

    Article  CAS  PubMed  Google Scholar 

  40. Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32:507–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Roberts SE, Goldacre MJ, Neil H. Mortality in young people admitted to hospital for diabetes: database study. BMJ. 2004;328(7442):741–2.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Von Mach MA, Gauer M, Meyer S, Omogbehin B, Schinzel H. Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding original sulfonylureas, biguanides and insulin. Int J Clin Pharmacol Ther. 2006;44(2):51–4.

    Article  Google Scholar 

  43. Lustmann PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behaviour therapy for depression in type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med. 1998;129(8):613–21.

    Article  Google Scholar 

  44. Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15–22.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Markowitz S, Gonzalez JS, Wilkinson JL, Safren SA. Treating depression in diabetes: emerging findings. Psychosomatics. 2011;52:1–18.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Georgiades A, Zucker N, Friedman KE, Mosunic CJ, Applegate K, et al. Changes in depressive symptoms and glycemic control in diabetes mellitus. Psychosom Med. 2007;69(3):235–41.

    Article  CAS  PubMed  Google Scholar 

  47. Steed L, Cooke D, Newman S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns. 2003;51(1):5–15.

    Article  PubMed  Google Scholar 

  48. Wang MY, Tsai PS, Chou KR, Chen CM. A systematic review of the efficacy of non-pharmacological treatments for depression on glycemic control in type 2 diabetics. J Clin Nurs. 2008;17(19):2524–30.

    Article  PubMed  Google Scholar 

  49. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry. 2007;46:1123–31.

    Article  Google Scholar 

  50. NICE. Schizophrenia: core intervention in the treatment and management of schizophrenia in adults in primary and secondary care. 2008. http://www.nice.org.uk/guidance/index.jsp?action=download&o=42139. Zugegriffen: 12. Aug. 2015.

  51. Correll C, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internistisches Zentrum, Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Baumgartner Höhe 1, 1140, Wien, Österreich

    Heidemarie Abrahamian

  2. Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich

    Alexandra Kautzky-Willer

  3. 1. Psychiatrische Abteilung mit Zentrum für Psychotherapie und Psychosomatik, Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Wien, Österreich

    Angelika Rießland-Seifert

  4. 5. Medizinische Abteilung Wilhelminenspital der Stadt Wien, Wien, Österreich

    Peter Fasching

  5. Universitätsklinik für Innere Medizin I, Medizinische Universität Innsbruck, Innsbruck, Österreich

    Christoph Ebenbichler

  6. Universitätsklinik für Psychiatrie, Medizinische Universität Graz, Graz, Österreich

    Peter Hofmann

  7. Lipidstoffwechselambulanz, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich

    Hermann Toplak

Authors
  1. Heidemarie Abrahamian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandra Kautzky-Willer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angelika Rießland-Seifert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Fasching
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christoph Ebenbichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hermann Toplak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heidemarie Abrahamian.

Ethics declarations

Interessenkonflikt

H. Abrahamian hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Germania Pharmazeutika, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, Servier, Takeda.

A. Kautzky-Willer hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: AstraZeneca, Bayer Health Care, Bristol-Myers Squibb, GlaxoSmithKline Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis.

A. Rießland-Seifert hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: AstraZeneca, Bristol-Myers Squibb, Eli Lilly.

P. Fasching hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott, AstraZeneca, Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Germania Pharmazeutika, GlaxoSmithKline Pharma, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, sanofi-aventis, Servier, Takeda. Zusätzlich gibt P. Fasching an, dass für ihn persönlich kein Interessenkonflikt vorliegt. Er legt offen, dass er in diesem Zeitraum von den genannten Firmen Honorare für Vorträge und Consulting erhalten hat bzw. Fortbildungsunterstützung im Rahmen der (dienst)rechtlichen Rahmenbedingungen bezogen hat (Einladung zu Kongressen) bzw. Klinische Studien als PI mit einzelnen Firmen durchgeführt hat bzw. durchführt.

C. Ebenbichler hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott Austria, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, Takeda.

P. Hofmann hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: AstraZeneca, Bristol-Myers Squibb, Germania Pharmazeutika, GlaxoSmithKline Pharma, Johnson & Johnson Medical, Eli Lilly, Novartis, Novo Nordisk, Pfizer, sanofi-aventis, Servier.

H. Toplak hat von folgenden Unternehmen, die teilweise fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Amgen, AstraZeneca, Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Certmedica, Germania Phamazeutika, Insumed, Johnson & Johnson Medical, Eli Lillly, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Omron Germany, Pfizer, Roche, sanofi-aventis, Takeda, Vivus.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abrahamian, H., Kautzky-Willer, A., Rießland-Seifert, A. et al. Psychische Erkrankungen und Diabetes mellitus. Wien Klin Wochenschr 128 (Suppl 2), 170–178 (2016). https://doi.org/10.1007/s00508-015-0939-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-015-0939-8

Schlüsselwörter

Keywords

Search

Navigation